Publications by authors named "N S Jessop"
Article Synopsis
- - Patients with multiple sclerosis (PwMS) face a higher risk of infections, especially those treated with ocrelizumab (OCR), as shown in a study involving 6,155 patients over a median period of 3.7 years.
- - Serious infections (SIs) were reported at an incidence rate of 1.50 per 100 patient years for relapsing MS and 3.70 for progressive MS, with lower respiratory, urinary, abdominal, gastrointestinal, and skin infections being the most common.
- - Significant risk factors for SIs included comorbidities, recent relapses, and higher disability scores, particularly in patients with progressive MS where a high EDSS score indicated a fourfold increase in
Laboratory research in Ghana demonstrated the effectiveness of an isolate of Beauveria bassiana (IMI 389521) from the United Kingdom against the larger grain borer Prostephanus truncatus (Horn) (Coleoptera: Bostrichidae), a major pest of stored maize. The minimum effective concentration, following artificial infestation trials on maize, was between 10 and 10 cfu/kg maize. Before moving out to village-level control, a major requirement was to determine if the product could effect control in artificially infested maize held under real environmental conditions in several locations in Ghana.
View Article and Find Full Text PDFBackground: The use and potential benefit of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies (mAbs) for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in people living with multiple sclerosis (pwMS) remains poorly studied. The objective of this study is to describe the therapeutic use of anti-SARS-CoV-2 mAbs among pwMS.
Methods: This retrospective cohort study used electronic medical records data from the TriNetX Dataworks USA Network and included adult pwMS, diagnosed with COVID-19, who received anti-SARS-CoV-2 mAbs in the outpatient setting between November 2020 and April 2022.
Article Synopsis
- Targeted therapy for patients with EGFR-mutant lung cancer is more effective than standard treatments, and timely detection of mutations can enhance management of the disease.
- An intervention was developed to speed up the initiation of osimertinib treatment by integrating workflows across radiology, pathology, and pharmacy, significantly reducing the time to get testing results and start treatment.
- The study showed that the new approach decreased the median time from biopsy to EGFR testing results and treatment initiation, allowing for quicker access to osimertinib for patients compared to traditional methods.
Introduction: During the COVID-19 pandemic, electronic health record (EHR) data has been used to investigate disease severity and risk factors for severe COVID-19 in people with multiple sclerosis (pwMS). Methodological challenges including sampling bias, and residual confounding should be considered when conducting EHR-based studies. We aimed to address these limitations related to the use of EHR data in order to identify risk factors, including the use of disease modifying therapies (DMTs), associated with hospitalization for COVID-19 amongst pwMS.
View Article and Find Full Text PDF